🦊/Companies

Terns Pharmaceuticals

Foster City, US · Founded 2020 · Delaware corporation · 4 known investors

Find your way into Terns Pharmaceuticals

105 people in our graph share verified history with the Terns Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.

Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program. As of May 5, 2026, it operates as a subsidiary of Merck & Co., Inc. (known as MSD outside the US and Canada).

Founders & leadership

MV
Mark Vignola, Ph.D.Executive
BYBryan Yoon
Bryan YooninChief Operating Officer & General Counsel2020–2024
SSSenthil Sundaram
Senthil SundaraminChief Executive OfficerSenthil Sundaram is a biotechnology executive with approximately two decades of experience in finance, organizational development, clinical development, regulatory affairs, and manufacturing across emerging biopharmaceutical companies focused on liver disease and genetic medicines. He has led fundraising efforts exceeding $1.7 billion and negotiated multiple licensing and acquisition transactions.
WZ
Weidong Zhong, Ph.D.Named on SEC filing
JQJill Quigley
Jill QuigleyinMember of the Board of Directors; Audit ChairDirector at Chemomab
DF
David FellowsNamed on SEC filing
EW
Elise WangNamed on SEC filing

Board

YS
Yi Shi, Ph.D.Board director
HL
Hongbo Lu, Ph.D.Board director
CG
Carl Gordon, Ph.D.Board director
JK
Jeffrey KindlerBoard director

Investors · 4

Funding

SEC filings, press & company announcements

$97.7M disclosed across 1 of 3 rounds · 2020–2025

  • Undisclosed amountpublic offeringDec 2025
    Source ↗
  • Undisclosed amountfollow-on equity offeringDec 2025
    Source ↗
$97.7MraisedJan 2021 · 13 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Weidong Zhong, Ph.D.Executive Officer, Director
  • Jill QuigleyDirector
  • David FellowsDirector
  • Jeffrey KindlerDirector
  • Mark Vignola, Ph.D.Executive Officer
  • Bryan YoonExecutive Officer
  • Yi Shi, Ph.D.Director
  • Hongbo Lu, Ph.D.Director
  • Carl Gordon, Ph.D.Director
  • Elise WangDirector
  • Senthil SundaramDirector, Executive Officer
Offering amount
$97.7M
Amount sold
$97.7M
First sale
Dec 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Companies competing with Terns Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Terns Pharmaceuticals do?
Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program. As of May 5, 2026, it operates as a subsidiary of Merck & Co., Inc. (known as MSD outside the US and Canada).
Who are Terns Pharmaceuticals's investors?
Terns Pharmaceuticals's investors include Decheng Capital, LAV, Lilly Asia Ventures, Vivo Capital.
How much funding has Terns Pharmaceuticals raised?
Terns Pharmaceuticals has disclosed $97.7M raised across 1 of its 3 known rounds.
Where is Terns Pharmaceuticals headquartered?
Terns Pharmaceuticals is headquartered in Foster City, US.